Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 2Recurrence 1Neoplasm Metastasis 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 8Capecitabine 6pembrolizumab 5Carboplatin 5Pemetrexed 3Paclitaxel 3Oxaliplatin 3Irinotecan 3regorafenib 2osimertinib 2Taxes 2Sunitinib 2Radiotherapy 2Fluorouracil 2Cisplatin 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tislelizumab 1tegafur-gimeracil-oteracil 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1sintilimab 1seribantumab 1selinexor 1ruxolitinib 1rubitecan 1pralsetinib 1palbociclib 1olaparib 1niraparib 1linifanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma × PEGPH20 × Clear all
NCT02487277 2020-01-02

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

University of California, San Francisco

Phase 2 Terminated
3 enrolled 8 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡